How do multi-stage, multi-arm trials compare to the traditional two-arm parallel group design - a reanalysis of 4 trials

被引:26
作者
Barthel, F. M-S [1 ,2 ,3 ]
Parmar, M. K. B. [2 ,3 ]
Royston, P. [2 ,3 ]
机构
[1] Kings Coll London, Dept Biostat, Inst Psychiat, London WC2R 2LS, England
[2] GlaxoSmithKline Inc, Oncol R&D, London, England
[3] MRC, Clin Trials Unit, London, England
来源
TRIALS | 2009年 / 10卷
关键词
RANDOMIZED CONTROLLED-TRIAL; OVARIAN-CANCER; CLINICAL-TRIALS; CHEMOTHERAPY; SURVIVAL; WOMEN;
D O I
10.1186/1745-6215-10-21
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: To speed up the evaluation of new therapies, the multi-arm, multi-stage trial design was suggested previously by the authors. Methods: In this paper, we evaluate the performance of the two-stage, multi-arm design using four cancer trials conducted at the MRC CTU. The performance of the design at fictitious interim analyses is assessed using a conditional bootstrap approach. Results: Two main aims are addressed: the error rate of correctly carrying on/stopping the trial at an interim analysis as well as quantifying the gains in terms of resources by employing this design. Furthermore, we make suggestions for the best timing of this interim analysis. Conclusion: Multi-arm, multi-stage trials are an effective way of speeding up the therapy evaluation process. The design performs well in terms of the type I and II error rates.
引用
收藏
页数:10
相关论文
共 12 条
  • [1] [Anonymous], 2007, SURVIVAL ANAL PRACTI
  • [2] BARTHEL F, 2009, STATA J IN PRESS
  • [3] Interim futility analysis with intermediate endpoints
    Goldman, Bryan
    LeBlanc, Michael
    Crowley, John
    [J]. CLINICAL TRIALS, 2008, 5 (01) : 14 - 22
  • [4] Good P. I., 2001, Resampling methods: A practical guide to data analysis, V2nd ed.
  • [5] DISCRETE SEQUENTIAL BOUNDARIES FOR CLINICAL-TRIALS
    LAN, KKG
    DEMETS, DL
    [J]. BIOMETRIKA, 1983, 70 (03) : 659 - 663
  • [6] Interim monitoring of group sequential trials using spending functions for the type I and type II error probabilities
    Pampallona, S
    Tsiatis, A
    Kim, K
    [J]. DRUG INFORMATION JOURNAL, 2001, 35 (04): : 1113 - 1121
  • [7] Parmar MKB, 2003, LANCET, V361, P2099
  • [8] Parmar MKB, 2002, LANCET, V360, P505
  • [9] Ritchie A, 1999, LANCET, V353, P14
  • [10] Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer
    Royston, P
    Parmar, MKB
    Qian, W
    [J]. STATISTICS IN MEDICINE, 2003, 22 (14) : 2239 - 2256